Obamacare Enrollment: Quantity OK, Quality Questionable?
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 12:00PM CDT
Quantity versus quality? The age-old question appears to have raised its head again with the latest information about enrollment in the Affordable Care Act, commonly referred to as Obamacare. According to the White House, over 7.5 million Americans...
Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress(TM) 2014 of the European Association for the Study of the Liver (EASL)
Business Wire - Sat Apr 12, 10:24AM CDT
Janssen R&D Ireland (Janssen) today announced positive new data from the clinical development programme of simeprevir, including final data from cohort 2 of the Phase 2 COSMOS study of the protease inhibitor simeprevir administered once daily with Gilead Sciences Inc.'s nucleotide inhibitor sofosbuvir, with and without ribavirin (RBV), in adult patients chronically infected with genotype 1 hepatitis C virus (HCV). The final data, along with an additional analysis from COSMOS cohort 1 and new subgroup analyses of Phase 3 data in European and genotype 4 HCV patients, were presented at The International Liver Congress(TM) 2014 of the European Association for the Study of the Liver (EASL) in London.
The Hepatitis C Cure Poised to "Break the Country"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Apr 12, 7:05AM CDT
Gilead 's Sovaldi is reportedly flying off the shelves, but bad press due to pushback from payers, members of Congress, and even the WHO continues to roll in. At issue is the high price of Sovaldi in the U.S. -- $84,000 for a full course of...
Most active Nasdaq-traded stocks
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Encouraging Results on Gilead's Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:15PM CDT
Gilead announced encouraging results from two phase II studies and a compassionate access study on Sovaldi.
JPMorgan's Earnings Disaster Drops the Dow 100 Points
Dan Carroll, The Motley Fool - Motley Fool - Fri Apr 11, 1:38PM CDT
Earnings season has swung around hard on the market today, as the Dow Jones Industrial Average tumbled 130 points as of 2:30 p.m. EDT following some ugly numbers from one of America's top big banks. All but a handful of blue-chip stocks are in...
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Fri Apr 11, 12:58PM CDT
Gilead Sciences (GILD) shares are up 3.9% to $67.98 in trading on Friday following Texas health board reconsideration
Midday Glance: Biotechnology companies
AP - Fri Apr 11, 12:51PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Drying Stimulus Tap Is Sore Spot for Tech Stocks
at The Street - Fri Apr 11, 12:50PM CDT
The drying stimulus tap rather than stretched valuations has been the trigger for recent selling in tech and biotech shares, some managers argue, claiming this makes another tech sector crash unlikely.
Encouraging Data from Bristol-Myers - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 10:30AM CDT
Bristol-Myers announced positive data on its HCV cocktail treatment from a late stage study.
Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.
Stock Market News for April 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 9:06AM CDT
Benchmarks ended in the red zone yesterday, once again dragged down by declines in momentum and bio-tech stocks
Merck Shouts "Me, Too!" But Will It Matter?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 11, 8:30AM CDT
Merck has rolled out impressive phase 2 data that shows that it too has a very compelling hepatitis C regimen that may eliminate the use of side-effect laden Peginterferon and ribavirin -- the standard of care just a few short years ago. But...
Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.